Just months after picking up Advanced Accelerator Applications in a $3.9 billion buyout, Novartis is getting a quick boost with the U.S. approval for Lutathera. More: Novartis wins FDA nod for newly acquired cancer drug Lutathera Source: fierce
read moreRoche and Shire are taking their hemophilia battle across the pond. Following Shire’s EU approval for Adynovi last week, Roche has nabbed a European green light for Hemlibra, a first-in-class hemophilia A medication that analysts expect to reach blockbuster heights.
read moreSanofi has worked hard to hold on to the big profits generated by its blockbuster insulin Lantus, but the onslaught of copies continues. Mylan and Biocon have now won an EU recommendation for approval of their biosimilar after overcoming manufacturing
read moreAfter picking up key regulatory nods in the U.S., GlaxoSmithKline’s Shingrix is well on its way to expanding its reach into Europe. This week, the European Medicines Agency’s CHMP recommended the vaccine for shingles prevention in people 50 and over.
read moreThe benefits of the upcoming tax overhaul will be so great that AbbVie is planning $2.5 billion in capital projects in the U.S., plus a pension and compensation boost for employees, it said during its fourth-quarter earnings release. But the
read moreEdinburgh, Scotland based Synpromics has teamed up with UCL Great Ormond Street Institute of Child Health to develop novel gene therapies for diseases affecting the haematopoietic system. More: Scotland’s Synpromics expands gene therapy work with UCL deal Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals